Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve Patients with Advanced or Metastatic Non-Clear Cell RCC By Ogkologos - April 15, 2025 474 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUNNIFORECAST study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Elacestrant July 26, 2023 EMA Recommends Granting a Marketing Authorisation for Tebentafusp March 31, 2022 FDA Warns That Robotic Surgery May Lower Life Expectancy for Breast... March 1, 2019 2021/22 in review: Charity looks to the future with ambitious new... July 21, 2022 Load more HOT NEWS A Positive Trend in OS Improvement Favours Atezolizumab Compared to Best... How to Talk About Advanced Cancer Care Planning: An Expert Discussion Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer Cell Phone Use May Increase Risk of Breast and Thyroid Cancer,...
